| Name | Title | Contact Details |
|---|
AEGEA Medical was founded in 2008 to develop technology that aspires to utilize water vapor to treat a variety of women`s health conditions. Led by an experienced management team, and supported by a committed investor group, AEGEA Medical has established an expanding Intellectual Property (IP) portfolio.
Founded in 2004, BioRx is a national provider of specialty pharmacy, infusion management and industry consulting services. As a private, independently-owned company, BioRx is committed to a flexible service model that meets the needs of its customers, including consumers, healthcare providers, health plans and pharmaceutical manufacturers. The company’s streamlined management structure allows it to respond more quickly to changes in the marketplace and provide a higher level of service that is customized for each consumer. Moreover, BioRx helps to provide a more cost-effective level of healthcare – in particular by moving patients from costly facility-based infusion sites to their homes, thereby allowing us to closely monitor the administration and outcomes of complex infusion therapies. BioRx consumer services include home delivery of specialty intravenous and injectable pharmaceuticals, medical supplies, nursing support, reimbursement coordination, consumer advocacy, and highly customized care plans. The company also provides professional consulting services to business partners within the insurance and pharmaceutical manufacturing industries.
South Alamo Medical Group is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Apostolic Christian Resthaven is a Elgin, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Celator Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is transforming the science of combination therapy and developing products to improve outcomes for patients with cancer. The Company is working to establish a new treatment paradigm in which rationally-designed, fully-integrated combination products replace combination regimens of individual agents. Celator`s proprietary technology platform, CombiPlex®, identifies the most effective synergistic ratio of the component drugs, optimizes the pharmacology of the drug combination prior to human clinical trials, allows simultaneous administration of the components as a single product and maintains the synergistic ratio of the components after administration thereby exposing tumor cells to the right amounts of drug for the right length of time.